tom dayspring

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part V, Peter and Tom talk about inflammation, endothelial health, and oxidative stress as they pertain to cardiovascular disease, and our attempts to monitor them using biomarkers. They also discuss a couple of very important risk factors that too few people (and doctors) know about. Tom closes the five-part series with a tragic story about his good friend that is likely all-too-common for many practicing physicians, that both haunts and motivates Dr. Dayspring to learn as much as he can about the number one killer in the United States.

We discuss:

•     Lp(a) [2:30];
•     Inflammation [17:15];
•     Oxidative stress markers: Lp-PLA2 and oxLDL [20:45];
•     Endothelial health markers: ADMA and SDMA [34:30];
•     Remnants [43:45];
•     Omega-3 fatty acids (EPA and DHA) and apoC-III [55:30];
•     Red blood cells and cholesterol transport [1:07:45];
•     Tom's friend Earl [1:10:00];
•     Peter's friend JP [1:18:15]; and
•     More.

Learn more at www.PeterAttiaMD.com

Connect with Peter on Facebook | Twitter | Instagram.

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part IV, Peter and Tom review the history and current use of drugs to prevent cardiovascular disease. They also discuss why some drugs appear to be more effective than others, an in-depth conversation about niacin, cholesterol and brain health, and the futility of using CKs (creatinine kinase) and liver function tests to identify adverse effects in statins, to name a few topics in this episode.

We discuss:

• Bile acid sequestrants and statins [2:00];
• Ezetimibe (Zetia) [15:00];
• PCSK9 inhibitors [27:30];
• Fibrates [41:00];
• Fish oil, DHA, and EPA [1:01:00];
• Niacin [1:05:15];
• PCSK9 inhibitors [1:23:45];
• Cholesterol, statins, and the brain [1:30:00];
• Elevated creatine kinase (CK) and liver function tests (LFTs) on statins [1:50:30]; and
• More.

Learn more at www.PeterAttiaMD.com

Connect with Peter on Facebook | Twitter | Instagram.

In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into HDL, why "reverse cholesterol transport" is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials.

We discuss:

• Reverse cholesterol transport [1:40];
• Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00];
• Remnant lipoproteins and apoC-III [16:45];
• Particles having sex: lipid exchange [28:00];
• Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45];
• 2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45];
• 2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15];
• 2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and
• More.

Learn more at www.PeterAttiaMD.com

Connect with Peter on Facebook | Twitter | Instagram.